Healthy subjects were given single intravenous doses of ciprofloxacin, azlocilin, and the two drugs simultaneously on separate occasions. High-pressure liquid chromatographic analysis was used to assay the concentrations of both drugs in serum and urine. Pharmacokinetic parameters were calculated by noncompartmental methods. The total body (CL), renal (CLR), and nonrenal (CLNR) clearances; steady-state volume of distribution (V.); and fractional urinary excretion of ciprofloxacin were all markedly decreased with the simultaneous administration of azlocillin. The disposition of azlocillin was unchanged when it was given with ciprofloxacin compared to when it was given alone. The pharmacokinetic parameters (mean ± standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 ± 9.2 versus 33.9 ± 6.0 liters/h (P < 0.0005); CLR, 26.5 _ 4.8 versus 16.2 ± 4.2 liters/h (P < 0.0005); CLNR, 25.8 ± 5.5 versus 17.7 ± 4.0 liters/h (P < 0.03); V., 224 ± 30 versus 166 ± 41 liters (P < 0.01); fractional urinary excretion, 0.56 ± 0.06 versus 0.43 ± 0.04 (P < 0.002), respectively. This interaction resulted in significantly higher and more prolonged concentrations of ciprofloxacin in serum, which may be beneficial in the treatment of serious gram-negative bacterial infections, but it could also produce greater toxicity or result in more pronounced effects on oxidative drug metabolism of other medications.
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Ciprofloxacin, a fluorinated quinolone, and azlocillin, a ureidopenicillin, may potentially be used in combination for the treatment of gram-negative bacterial infections (3) . It has been demonstrated, in experimental models of infection, that azlocillin can prevent the emergence of ciprofloxacin-resistant mutants of Pseudomonas aeruginosa (11) . Additionally, the drugs in combination may exert a synergistic effect against selected organisms such as P. aeruginosa (1) .
Both ciprofloxacin and azlocillin are eliminated by the renal (tubular secretion, glomerular filtration) and hepatic (biliary excretion, metabolism) routes (2, 7, 10) . Both are organic acids and, therefore, may compete for elimination if they are given together. This would potentially increase and prolong the concentrations of one or both drugs in serum.
Thus, the purpose of this study was to determine whether the simultaneous administration of parenteral ciprofloxacin and azlocillin results in altered elimination of either or both drugs.
MATERLALS AND METHODS
Dosage regimens and subjects. Six healthy male volunteers (age, 22 + 3 years; weight, 77 ± 13 kg) received single doses of ciprofloxacin (4 mg/kg intravenously), azlocillin (60 mg/kg intravenously) and the two drugs simultaneously on three separate occasions separated by at least 1 week. Both drugs were diluted to a final volume of 50 ml in suitable vehicles and administered as a constant-rate infusion with a syringe pump over 30 min. Informed consent was obtained from each subject before his participation in the study, and the experimental protocol was approved by and conducted within the guidelines set forth by the Human Subjects Committee of the University of California, Los Angeles, * Corresponding author.
School of Medicine. Physical examinations and laboratory tests were performed to rule out any underlying disease.
Blood and urine sampling. Blood samples for drug concentration determinations were collected from each subject at the end of a 0.5-h intravenous infusion and at 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 14 h from the start of infusion. Urine was collected from 0 to 2, 2 to 4, 4 Mezlocillin, the internal standard, was used in solution in acetonitrile at 20 ,g/ml. Briefly, the assay was carried out by adding 1.0 ml of internal standard solution to 0.200 ml of serum, followed by mixing with a vortex mixer and centrifugation. A total of 10 or 20 Rl of the organic phase was injected onto the column, the azlocillin and mezlocillin peak heights were determined with the integrator, and their ratios were calculated. Typical retention times for azlocillin and mezlocillin were 10.1 and 12.9 min, respectively. A calibration curve was constructed by least-square linear regression analysis of the peak height ratio on azlocillin concentrations. The assay showed linearity in both concentration ranges used for the standard curves: 0 to 20 and 20 to 200 ,ug/ml. Inter-and intraday variations of the assay, which was performed on samples containing approximately 90 p.g/ml, ranged from 1.2 to 5.2%. Assay of azlocillin in urine was identical to that for assay of azlocillin in serum, except that standards were prepared in normal human urine that was diluted 1:20 with water.
(ii) Ciprofloxacin assay. Ciprofloxacin was assayed in serum and urine by a high-pressure liquid chromatographic method described previously (6) . Assays were performed after sample dilution with 0.1 N phosphoric acid. Internal standards were prepared by using the isopropyl analog of ciprofloxacin in the same buffer. Urine samples were assayed by using a polystyrene-divinyl benzene column with UV absorbance detection. The mobile phase for this system consisted of acetonitrile, methanol, and trichloroacetic acid, with the pH adjusted to 3 with 1 N NaOH. Serum samples were assayed by using acetonitrile and tetrabutylammonium bromide, and the pH was adjusted to 2.5 with phosphoric acid. Ciprofloxacin was measured spectrofluorometrically since it has native fluorescence. Quantitation of ciprofloxacin was based on peak height ratios. Assays were highly specific, with a minimum detection limit of 0.01 ,ug/ml. The assay showed linearity in both concentration ranges used for the standard curves: 0 to 3 and 3 to 50 p.g/ml. The intra-and interday coefficients of variation, which were determined for samples containing approximately 3 ,g/ml, ranged from 4 to 9%.
Pharmacokinetic analysis. The elimination half-lives (tv2) of the compounds were determined by nonlinear regression analysis of the elimination phases of the plotted serum concentration versus time curves and division of the slope of the line into the natural logarithm of 2. The weighting scheme used was the inverse of the observed value squared. Additionally, all of the datum points were fit to an open two-compartment body model to generate a more precise value for the elimination rate constants. However, these did not differ significantly from the variables that were generated previously. Other pharmacokinetic parameters were calculated by noncompartmental methods (4). The area under the curve (AUC) was calculated by the log trapezoidal rule method; total body clearance (CL) was calculated by the equation CL = dose/AUC. Renal clearance (CLR) was calculated by the equation CLR = Aet1_t2/AUCt1.t2, where Ae is the amount excreted in urine during the time interval tl and t2, and AUC is the area under the serum concentrationversus-time curve during the same time interval. The mean CLR was calculated for each subject from the five interval determinations over the first 12 h. Nonrenal clearance (CLNR) was calculated by subtracting CLR from CL.
The steady-state volume of distribution (V55) was calculated by the equation Vs5 = [CL x (AUMC/AUC)] - [(t/2) CLI, where AUMC is the area under the first moment of the serum concentration versus time curve and t is the infusion duration (4).
Statistical analysis. Mean data for each drug given alone were compared with the results obtained from the combined administration by the paired Student t test and the Wilcoxon signed rank test. A P value of s0.05 was considered significant.
RESULTS
The pharmacokinetic disposition of azlocillin was unchanged, despite the simultaneous administration of ciprofloxacin ( Table 1) . Concentrations of azlocillin in serum and urine were virtually the same whether it was given alone or in combination with ciprofloxacin. The CL and V., of ciprofloxacin were significantly decreased by the simultaneous administration of azlocillin. The mean serum concentration-versus-time curves-for ciprofloxacin are depicted in Fig. 1 . Although the concentrations at the end of the infusion were nearly identical, thereafter the concentrations of ciprofloxacin, when given with azlocillin, were consistently greater. This resulted in a significantly decreased CL and Vs5 of ciprofloxacin (Table 2 ). The tj/ of the compound, however, was unchanged. CL, CLR, and CLNR were reduced by 35 , 39, and 31%, respectively. The V., was reduced by 27%.
As a result of reduced CLR, the fraction of a dose that was excreted unchanged in 24 h decreased, on average, from 0.56 to 0.43, a 23% change. The cumulative urinary excretion of ciprofloxacin is depicted in Fig. 2 . Ciprofloxacin excretion during the first 2-h collection period was substantially (55%) less when given in combination with azlocillin than when ciprofloxacin was given alone. This difference diminished to 46% by 6 h, 35% by 8 h, 28% by 12 h, and finally, 24% from 12 to 24 h. These changes in urinary excretion are reflected by the trends in CLR of the drug (Fig. 3) . When ciprofloxacin was given alone, CLR was high (35 liters/h) for the first 2 h and then stabilized to about 25 liters/h over the ensuing sampling periods. In contrast, when ciprofloxacin was given with azlocillin, CLR appeared to be stable and low (13 liters/h) for the first 4 h and then gradually increased to about 20 liters/h. DISCUSSION The interference with beta-lactam elimination by probenecid is well described. The mechanism of this interaction is inhibition of the transport of the beta-lactam in the renal tubule. We and others have explored the possibility that the two different antimicrobial agents produce a similar interaction. Rodondi et al. (9) have described a significant reduction in the clearance of cefotaxime with concomitant mezlocillin administration. This interaction involved two beta-lactam antibiotics, both of which are subject to glomerular filtration and tubular secretion. Kampf et al. (5) have shown that azlocilhin can affect the clearance of cefotaxime in a similar fashion. Both of those studies (5, 9) also demonstrated a significant reduction in the CLNR of cefotaxime. A delay and reduction in the formation of the desacetyl metabolite of cefotaxime was found in both investigations.
The present study represents the only experience in humans thus far with antibacterial compounds that are dissimilar in structure. Ciprofloxacin, a quinolone, and azlocillin are both secreted at the proximal tubule. We have demonstrated that azlocillin significantly reduces the renal excretion of ciprofloxacin, presumably from competition for tubular secretion. Peterson et al. (8) have reported similar findings in rabbits. Since neither of these compounds is significantly bound to serum albumin, it is possible that glomerular filtration partially compensated for the reduction in tubular secretion. However, the net effect was a 35% decrease in the CL of ciprofloxacin. Interestingly, both renal and nonrenal elimination were affected, suggesting interference by azlocillin with the hepatic clearance of ciprofloxacin. Both compounds undergo biliary excretion, metabolism, or both; therefore, this is a possible explanation. We are assessing the disposition of the ciprofloxacin metabolite, Ml, by analysis of urinary excretion.
As noted above, when given with azlocillin, the CLR of ciprofloxacin is significantly lower than when given alone for the first 4 h. We feel that this is attributable to competition for renal tubular secretion by azlocillin. The tj12 of azlocillin was only slightly greater than 1 h; this is consistent with the presence of significant quantities of azlocillin in the kidney. Repeated doses of azlocillin given every 4 to 6 h should have even more pronounced effects.
The disposition of azlocillin was unchanged. However, we would have predicted the interaction to be unidirectional since the molar amounts of each drug administered were 1.54 M/kg for ciprofloxacin and 27.7 M/kg for azlocillin. Thus, it seems that quantitative competition for elimination favored the prevention of ciprofloxacin elimination and, possibly, distribution.
The alteration in the V., produced by the interaction is poorly understood. We cannot rule out actual alterations in drug distribution, since estimation of this parameter at steady state directly indicates equilibrium distribution mechanisms (4) .
Since it has been demonstrated that cefotaxime metabolite formation is slowed by azlocillin and mezlocillin, inhibition of hepatic uptake may explain the decrease in CLNR for ciprofloxacin as well.
The clearance of ciprofloxacin when it was given alone was approximately 52 liters/h. This value is greater than that observed in other studies of intravenous ciprofloxacin (range, 27 to 47 liters/h) ( 
